Select Publications
Journal articles
2024, 'Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes', Journal of the American College of Cardiology, 84, pp. 2246 - 2250, http://dx.doi.org/10.1016/j.jacc.2024.08.006
,2024, 'Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron', Journal of the American College of Cardiology, 84, pp. 1718 - 1720, http://dx.doi.org/10.1016/j.jacc.2024.09.013
,2024, 'Canagliflozin and iron metabolism in the CREDENCE trial.', Nephrol Dial Transplant, http://dx.doi.org/10.1093/ndt/gfae198
,2024, 'Risk of Relapse of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids', Arthritis and Rheumatology, 76, pp. 1431 - 1438, http://dx.doi.org/10.1002/art.42843
,2024, 'Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.', Circulation, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.071689
,2024, 'Normalizing serum phosphate based on association, not causation? Lessons in dialysis should have taught us not to fix what we can't prove is broken', Kidney International, 106, pp. 195 - 199, http://dx.doi.org/10.1016/j.kint.2024.05.020
,2024, 'Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence', Clinical Kidney Journal, 17, http://dx.doi.org/10.1093/ckj/sfae227
,2024, 'Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.', Nephrol Dial Transplant, http://dx.doi.org/10.1093/ndt/gfae156
,2024, 'Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)', American Journal of Respiratory and Critical Care Medicine, 209, pp. 1141 - 1151, http://dx.doi.org/10.1164/rccm.202308-1426OC
,2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023
,2024, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial', Kidney International Reports, 9, pp. 347 - 355, http://dx.doi.org/10.1016/j.ekir.2023.11.024
,2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', The Lancet Regional Health - Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988
,2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022
,2024, 'Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis', Journal of the American Society of Nephrology, http://dx.doi.org/10.1681/ASN.0000000000000495
,2024, 'Vitamin D status and intermediate vascular and bone outcomes in chronic kidney disease: a secondary post hoc analysis of IMPROVE-CKD', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16516
,2024, 'Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bzcfkb63
,2024, 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.', NEJM Evid, 3, pp. EVIDoa2300189, http://dx.doi.org/10.1056/EVIDoa2300189
,2024, 'WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS', Kidney International Reports, 9, pp. S562 - S563, http://dx.doi.org/10.1016/j.ekir.2024.02.1183
,2023, 'The outcomes of patients with kidney failure due to focal segmental glomerulosclerosis (FSGS) in Australia and New Zealand: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0293721
,2023, 'Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 82, pp. 543 - 558, http://dx.doi.org/10.1053/j.ajkd.2023.04.003
,2023, 'Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study', European Heart Journal - Quality of Care and Clinical Outcomes, 9, pp. 621 - 631, http://dx.doi.org/10.1093/ehjqcco/qcac069
,2023, 'Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease', Kidney Medicine, 5, http://dx.doi.org/10.1016/j.xkme.2023.100691
,2023, 'SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review', Endocrine Connections, 12, http://dx.doi.org/10.1530/EC-23-0005
,2023, 'A meta-analysis of GFR slope as a surrogate endpoint for kidney failure', Nature Medicine, 29, pp. 1867 - 1876, http://dx.doi.org/10.1038/s41591-023-02418-0
,2023, 'Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada', Kidney Medicine, 5, http://dx.doi.org/10.1016/j.xkme.2023.100675
,2023, 'Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?', Nephrology, 28, pp. 97 - 108, http://dx.doi.org/10.1111/nep.14130
,2023, 'Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD', Clinical Journal of the American Society of Nephrology, 18, pp. 183 - 192, http://dx.doi.org/10.2215/CJN.0000000000000050
,2023, 'Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)', Canadian Journal of Kidney Health and Disease, 10, http://dx.doi.org/10.1177/20543581231169610
,2023, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140b
,2023, 'Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140c
,2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a
,2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a
,2022, 'Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice', Heart Lung and Circulation, 31, pp. 1604 - 1611, http://dx.doi.org/10.1016/j.hlc.2022.09.003
,2022, 'Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID): A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical practice', BMC Nephrology, 23, http://dx.doi.org/10.1186/s12882-022-02987-1
,2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772
,2022, 'Representativeness of the PDOPPS cohort compared to the Australian PD population', Peritoneal Dialysis International, 42, pp. 403 - 414, http://dx.doi.org/10.1177/08968608211056242
,2022, 'Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis', Clinical Kidney Journal, 15, pp. 1144 - 1151, http://dx.doi.org/10.1093/ckj/sfac030
,2022, 'International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival', Kidney360, 3, pp. 872 - 882, http://dx.doi.org/10.34067/KID.0006922021
,2022, 'Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis', Journal of Nephrology, 35, pp. 1159 - 1170, http://dx.doi.org/10.1007/s40620-022-01268-2
,2022, 'Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD', Journal of the American Society of Nephrology, 33, pp. 59 - 76, http://dx.doi.org/10.1681/ASN.2021040554
,2022, 'Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region', Nephrology, 27, pp. 35 - 43, http://dx.doi.org/10.1111/nep.13953
,2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 33, pp. 297 - 298, http://dx.doi.org/10.1681/asn.20223311s1297c
,2022, 'Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.', NEJM Evid, 1, pp. EVIDoa2100021, http://dx.doi.org/10.1056/EVIDoa2100021
,2021, 'Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease', Current Opinion in Nephrology and Hypertension, 30, pp. 467 - 473, http://dx.doi.org/10.1097/MNH.0000000000000728
,2021, 'Editor's note', Internal Medicine Journal, 51, pp. 1368, http://dx.doi.org/10.1111/imj.15462
,2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, 23, pp. 1420 - 1425, http://dx.doi.org/10.1111/dom.14351
,2021, 'Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease', Current Opinion in Nephrology and Hypertension, 30, pp. 346 - 352, http://dx.doi.org/10.1097/MNH.0000000000000699
,2021, 'A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes', Kidney International Reports, 6, pp. 695 - 705, http://dx.doi.org/10.1016/j.ekir.2020.12.019
,2021, 'Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease', Journal of Renal Nutrition, 31, pp. 155 - 163, http://dx.doi.org/10.1053/j.jrn.2020.02.007
,2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281
,